
Quicksome™: Building The Commercial Pathway
MLCO enters a strategic LOI with a U.S. 503A compounding pharmacy for Quicksome
Registration is open for our 2026 Annual General Meeting
RegisterViewRegister for The More Life Company's Annual General Meeting.
Questions? Reach us at ir@themorelife.company.

2026 AGM Materials
The Notice of Meeting, Management Information Circular, and Form of Proxy for the 2026 Annual General Meeting
Press releases, company updates, and coverage across our platforms.

MLCO enters a strategic LOI with a U.S. 503A compounding pharmacy for Quicksome

Strategic LOI advances U.S. compounding capability for a growing portfolio of potential Quicksome-enabled pharmaceutical applications

This morning we announced results from our exploratory human Quicksome™ testosterone study, and I am pleased to share why I believe this work represents an important step for the Company.

Eight-participant pharmacokinetic study shows rapid systemic appearance following administration of 5 mg and 15 mg Quicksome™ sublingual formulations

Up to 32.5% more special-grade yield and 27.6% more total yield versus control. The independently designed and conducted Brazilian trial showed the strongest Agrarius program adding 8.0 tonnes per hectare in the higher-value 45 to 70 mm category, lifting special-grade share to about 80.7% of total yield versus 76.4% in the control.
Independent randomized field trial recorded numerical increases of up to 32.5% in special-grade potato yield and up to 27.6% in total yield in the leading Agrarius application programs.

The More Life Company (formerly MVMD), announces the completion of its corporate name change and is pleased to announce that its common shares will continue to be quoted on the OTCID under the new trading symbol “TMLCF”.

This morning, we announced the completion of our corporate name change from Mountain Valley MD to The More Life Company.

The More Life Company, formerly Mountain Valley MD Holdings Inc. (CSE: MVMD) (OTC: MVMDF), is pleased to announce that it has completed a corporate name change.

This morning we announced the appointment of five additional advisors to MVMD,

The Company has appointed the five individuals listed below as advisors to provide strategic advisory services to the Company.

Quicksome™ Technology and the Emerging Peptide Opportunity